Email *

Message *

CANSWERIST® via @flipboard

Today's Tweets are Tomorrow's Posts
View my Flipboard Magazine.
View my Flipboard Magazine.
View my Flipboard Magazine.
View my Flipboard Magazine.

When you change the way you look at things, the things you look at change

Search This Blog

Sunday, March 30, 2008

A Possible Breakthrough?

[ALTACITIES.COM] ... ON THE RESEARCH PATH FOR NHL VACCINE: Accentia anticipates reporting a significant milestone in April, as the Company's majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), is preparing to report the interim unblinded results of its pivotal Phase 3 study for the anti-cancer vaccine, BiovaxID(TM). These results, if positive, are expected to poise BiovaxID to become the first personalized anti-cancer vaccine to ever be granted approval for the treatment of non-Hodgkin's lymphoma.

No comments:

SUBSCRIBE to This Blog

Enter your email address:

Delivered by FeedBurner

Today ▶ Canswerist®

▶ SLIDESHOW   ▶ NUZZEL “NEXT” story archive for 15Feb18 ▶ Alzheimer’s Cure in sight?   ▶ Health concerns for the 5...

Privacy Notice

Privacy Notice: The sites and blogs of ALTACITIES conform to these PRIVACY PRACTICES.